Coya 302: A Dual Mechanism Potential Biological Immunotherapy for ALS and FTD
Time: 11:30 am
day: Conference Day Two
Details:
- Treg dysfunction as a core driver of neurodegeneration in ALS and FTD
- Coya 302 targets adaptive and innate immune pathways
- Coya 302 as potential therapy for ALS and FTD
